Q2 26 EPS GAAP
$-0.07
BEAT +14.63%
Est. $-0.08
Q2 26 Revenue
$13.9M
BEAT +5.38%
Est. $13.2M
Market Reaction
Did APYX Beat Earnings? Q2 2026 Results
Apyx Medical Corp delivered a stronger-than-expected second quarter, beating Wall Street on both the top and bottom lines and extending its GAAP EPS beat streak to five consecutive quarters. The company posted Q2 2026 revenue of $13.88 million, up 22… Read more Apyx Medical Corp delivered a stronger-than-expected second quarter, beating Wall Street on both the top and bottom lines and extending its GAAP EPS beat streak to five consecutive quarters. The company posted Q2 2026 revenue of $13.88 million, up 22.1% year-over-year and ahead of the $13.18 million consensus estimate by 5.38%, while its GAAP net loss narrowed to $0.07 per share, beating the $0.08 consensus by 14.63%. The primary engine behind the outperformance was the Surgical Aesthetics segment, which grew 28% to $12.39 million, fueled by the AYON Body Contouring System and continued demand for the Renuvion platform across domestic and international markets. Gross margin widened to 63.9% from 62.3% a year ago, reflecting the richer mix of higher-margin aesthetics revenue. With FDA clearance of AYON's power liposuction capability secured and initial commercial shipments underway, management reaffirmed full-year 2026 revenue guidance of $59.0 million to $60.0 million, signaling confidence that AYON momentum will carry through the second half, and management is scheduled to discuss the outlook with investors at an upcoming growth conference in Boston.
Key Takeaways
- • AYON Body Contouring System commercial launch driving Surgical Aesthetics growth
- • Increased international generator sales
- • Higher volume of single-use handpieces domestically
- • Improved gross margin from favorable segment mix toward higher-margin Surgical Aesthetics
APYX Forward Guidance & Outlook
Apyx Medical reaffirmed its full-year 2026 financial guidance: total revenue of $59.0 million to $60.0 million (vs. $52.8 million in 2025), with Surgical Aesthetics revenue of $54.0 million to $55.0 million (vs. $45.3 million in 2025) and OEM revenue of approximately $5.0 million (vs. $7.5 million in 2025). Operating expenses are expected to remain below $45.0 million for the year. Management believes the company has sufficient cash to fund operations through 2027 based on AYON uptake, working capital management, and cost controls. AYON is expected to continue driving growth through the second half of 2026.
APYX YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
APYX Revenue by Segment
With YoY comparisons, source: SEC Filings
APYX Revenue by Geography
With YoY comparisons, source: SEC Filings
“We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported 28% growth for the Surgical Aesthetics segment and expect AYON to continue to drive growth through the second half of the year.”
— Charlie Goodwin, Q2 2026 Earnings Press Release
APYX Earnings Trends
APYX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
APYX EPS Trend
Earnings per share: estimate vs actual
APYX Revenue Trend
Quarterly revenue: estimate vs actual
APYX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.08 | $-0.07 | +14.63% | $13.9M | +5.38% |
| Q1 26 BEAT | $-0.10 | $-0.05 | +50.00% | $12.5M | +9.13% |
| Q4 25 BEAT FY | $-0.06 | $-0.03 | +46.43% | $19.2M | +0.21% |
| FY Full Year | $-0.30 | $-0.27 | +11.18% | $52.8M | +1.19% |
| Q3 25 BEAT | $-0.10 | $-0.05 | +51.22% | $12.9M | +7.30% |
| Q2 25 BEAT | $-0.09 | $-0.09 | +0.00% | $11.4M | -2.79% |
| Q1 25 BEAT | $-0.12 | $-0.10 | +13.04% | $9.4M | +1.04% |